Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

Go Back to All Clinical Trials

Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas

Brief description of study

This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.

Clinical Study Identifier: s20-01692

ClinicalTrials.gov Identifier: NCT04617002

Principal Investigator: Jessica Clymer.

Other Investigator: Devorah Segal.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies